Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Moderate Buy" from Analysts
Outlook Therapeutics, Inc. (NASDAQ:OTLK) has received a consensus rating of "Moderate Buy" from analysts. The stock has a 1-year price target of $46.43 and has been recommended as a buy by seven analysts. The company is focused on developing and commercializing monoclonal antibodies for ophthalmic indications. The stock's current price is $7.07.
Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $46.43.
Get Outlook Therapeutics alerts:
OTLK has been the topic of a number of recent research reports. Chardan Capital raised Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $60.00 price objective on the stock in a report on Thursday, February 15th. BTIG Research raised Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $50.00 price objective on the stock in a report on Wednesday, March 27th. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, May 17th. Finally, Capital One Financial reissued an "overweight" rating on shares of Outlook Therapeutics in a report on Friday, February 16th.
Check Out Our Latest Stock Report on Outlook Therapeutics
Hedge Funds Weigh In On Outlook Therapeutics
A hedge fund recently raised its stake in Outlook Therapeutics stock. Scotia Capital Inc. grew its position in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 420.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 338,439 shares of the company's stock after purchasing an additional 273,463 shares during the quarter. Scotia Capital Inc. owned approximately 0.13% of Outlook Therapeutics worth $75,000 as of its most recent SEC filing. 11.20% of the stock is owned by institutional investors.
Outlook Therapeutics Stock Performance
Shares of OTLK opened at $7.07 on Friday. The stock's 50-day simple moving average is $8.50 and its 200 day simple moving average is $8.33. The stock has a market capitalization of $165.51 million, a price-to-earnings ratio of -0.62 and a beta of 0.28. Outlook Therapeutics has a 52-week low of $4.00 and a 52-week high of $40.60.
About Outlook Therapeutics
(Get Free ReportOutlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
See Also
- Five stocks we like better than Outlook Therapeutics
- What Are Trending Stocks? Trending Stocks Explained
- MarketBeat Week in Review – 5/27 - 5/31
- Dividend Capture Strategy: What You Need to Know
- Foot Locker’s Quarter Sends Doubters Running
- What Is WallStreetBets and What Stocks Are They Targeting?
- Costco Wholesale Can Hit New Highs; A Rebound Is Coming
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ This military-backed stock “owns” AI market (From Porter & Company) (Ad)
Should you invest $1,000 in Outlook Therapeutics right now?
Before you consider Outlook Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.
While Outlook Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
